RxDoctor Payments Data

Ann Holmes, DO

Family Medicine · Fresno, CANPI 1225267966

Payments from drug & device makers

$11,671in general payments, 2019–2025

Across 626 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$798
  • Pfizer$609
  • Lilly USA, LLC$559
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,665100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,671 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$114,824
Medicare patients
266
Services billed
1,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate12$105,552
JardianceEmpagliflozin67$99,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$33,169
OzempicSemaglutide26$29,316
TrulicityDulaglutide26$26,836
JanuviaSitagliptin Phosphate12$19,002
EliquisApixaban11$18,338
Atorvastatin Calcium377$5,279
Albuterol Sulfate HfaAlbuterol Sulfate119$4,207
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen235$4,150
Levothyroxine Sodium258$3,823
Losartan Potassium302$3,317
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,273
Lisinopril195$2,433
Rosuvastatin Calcium135$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$297$99,69567 claims
GSKTrelegy Ellipta$301$33,16939 claims
Novo NordiskOzempic$798$29,31626 claims
Lilly USA, LLCTrulicity$559$26,83626 claims
MerckJanuvia$88$19,00212 claims
PfizerEliquis$609$18,33811 claims
AbbVieSynthroid$1,442$2,27346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →